
Jefferies Reaffirms Buy Rating on Protagonist Therapeutics, $121 Price Target
Jefferies has maintained a Buy rating on Protagonist Therapeutics (PTGX) with a price target of $121 for March 2026. This analyst update reflects continued positive outlook for the biotechnology…


